Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3107 in Advanced Malignant Tumors
NCT06413953Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3107 in cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
TQB3107
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06413953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413953.